Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia

被引：0
|
作者：
Shiyu He
Jinxia Zhao
Jialu Bian
Yinyu Zhao
Yuanyuan Li
Nan Guo
Lei Hu
Boyu Liu
Qianhang Shao
Huan He
Lin Huang
Qian Jiang
机构：
[1] Peking University People’s Hospital,Department of Pharmacy
[2] Peking University,Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences
[3] Beijing Children’s Hospital of Capital Medical University,Department of Pharmacy
[4] Peking University People’s Hospital,undefined
[5] Peking University Institute of Hematology,undefined
[6] National Clinical Research Center for Hematologic Disease,undefined
[7] Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,undefined
来源：
Pharmaceutical Research | 2023年 / 40卷
关键词：
chronic myeloid leukemia; dasatinib; individualized medicine; pharmacogenetics; population pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2413 / 2422
页数：9
相关论文
共 50 条
  • [41] Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia
    Serpa, Mariana
    Bendit, Israel
    Seguro, Fernanda
    Xavier, Flavia
    Cavalcante, Marcela
    Steinbaum, Daniel
    Nardinelli, Luciana
    Aldred, Vera Lucia
    de Paula, Henrique Moura
    Dorlhiac-Llacer, Pedro Enrique
    ACTA HAEMATOLOGICA, 2010, 124 (02) : 105 - 109
  • [42] Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib
    Hayashi, Yoshiki
    Nakamae, Hirohisa
    Katayama, Takako
    Nakane, Takahiko
    Koh, Hideo
    Nakamae, Mika
    Hirose, Asao
    Hagihara, Kiyoyuki
    Terada, Yoshiki
    Nakao, Yoshitaka
    Hino, Masayuki
    LEUKEMIA & LYMPHOMA, 2012, 53 (06) : 1084 - 1089
  • [43] Dasatinib inhibits coated-platelet generation in patients with chronic myeloid leukemia
    Mezei, Gabriella
    Debreceni, Ildiko Beke
    Kerenyi, Adrienne
    Remenyi, Gyula
    Szasz, Robert
    ILles, Arpad
    Kappelmayer, Janos
    Batar, Peter
    PLATELETS, 2019, 30 (07) : 836 - 843
  • [44] Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
    Miura, Masatomo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (05) : 645 - 654
  • [45] Dasatinib Dose Management for the Treatment of Chronic Myeloid Leukemia
    Talpaz, Moshe
    Saglio, Giuseppe
    Atallah, Ehab
    Rousselot, Philippe
    CANCER, 2018, 124 (08) : 1660 - 1672
  • [46] Dasatinib-Induced Chylothorax In Chronic Myeloid Leukemia
    Baloch, Z. A. Qutrio
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [47] Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
    Abbott, Brian L.
    CLINICAL THERAPEUTICS, 2012, 34 (02) : 272 - 281
  • [48] Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia
    Lima, Lisa M.
    Arellano, Martha
    Holloway, Stacie
    Shepard, Marian
    McMillan, Stephanie
    Khoury, Hanna Jean
    JOURNAL OF BLOOD MEDICINE, 2010, 1 : 221 - 225
  • [49] Dasatinib in chronic myeloid leukemia: A limited Indian experience
    Sharma, Atul
    Bahl, Ankur
    Raina, Vinod
    Kumar, Lalit
    Gupta, Ritu
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (04) : 375 - 379
  • [50] Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
    Ramchandren, Radhakrishnan
    Schiffer, Charles A.
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 205 - 214
12345